مرض الانسداد الرئوي المزمن مع النمط الظاهري اليوزيني عالي الخطورة: اليوزينيات الدموية ≥ 300 خلية/µL

References

DOI: 10.3390/jcm13020303

On the other hand, patients at high risk should be differentiated by phenotype: in the case of a non-acute and non-eosinophilic patient, treatment should be initiated with LABA + LAMA, and in the case of an eosinophilic patient, treatment should be initiated with IC + LABA (Figure 1).

Also, it proposes to initiate triple therapy (LABA + LAMA + IC) in patients with ≥300/µL blood eosinophils consistently and two or more moderate exacerbations or in those whose onset required an admission (Figure 2).